Contact us Demo our platform

ON DEMAND WEBINAR

Metabolomics in Multiomics Research: 5 Key Case Studies of Multiomics Research Driving Novel Insight Discovery

Multiomics research is crucial for understanding complex biological systems at a comprehensive level. By integrating data from genomics, transcriptomics, proteomics, metabolomics, and other omics disciplines, researchers can unravel intricate interactions and pathways within cells and organisms.

By helping researchers to more easily integrate multiomics data, multiomics studies can accelerate the path to novel actionable insights, identifying biomarkers and pathway associations that show the relationships and causalities of genetics, environment, and lifestyle on biological systems.

In this webinar, Brian Keppler, Ph.D., Director of Discovery and Translational Sciences at Metabolon, explores five publications that highlight the utility of multiomics research. These publications span different omic technologies and research applications which demonstrates the importance of multiomic insights.

About Metabolomics

Metabolomics, the study of small molecules, is integral to multiomics research. Analyzing metabolites complements genomics, proteomics, and transcriptomics, providing a snapshot of cellular function and metabolic changes. Combining metabolomics with other omics data enhances understanding of biological systems and adds additional insights into the phenotype.

You will learn:

  • How metabolomic data can be combined with genomics, proteomic, and microbiome analysis to produce novel insights into disease
  • Considerations for designing multiomic studies
  • Benefits of targeted and untargeted metabolomics approaches

Program

Presenter
Title/Abstract
Brian Keppler, Ph.D.
This section of the webinar discusses how metabolomics can provide insights that connect information across the central dogma of molecular biology. Dr. Keppler then discusses 3 of the 5 case studies presented in this webinar, outlined below:
  • Genome-wide association studies of metabolites in Finnish men identify disease-relevant loci
  • Multi-omics data integration reveals metabolome as the top predictor of the cervicovaginal microenvironment
  • Multi-omics of gut microbiome-host interactions in short- and long-term myalgic encephalomyelitis/chronic fatigue syndrome patients
Heino Heyman, Ph.D.
Achieving fast, accurate, and reproducible metabolomic data can be a challenging task that requires investing in people, technology, and novel methods to derive functional insights. In this short session, we demonstrate how Metabolon’s metabolomics-as-a-service solution can be leveraged to improve metabolite-level insights today.
Brian Keppler, Ph.D.
Dr. Keppler continues his presentation with the final 2 case studies:
  • Multiomics profiles of the intestinal microbiome in irritable bowel syndrome and its bowel habit subtypes
  • Molecular signatures of post-traumatic stress disorder in war-zone-exposed veteran and active-duty soldiers
Brian Keppler, Ph.D. & Heino Heyman, Ph.D.
Questions & Answers

Speakers

K
L

Brian Keppler, Ph.D.

Brian KepplerDirector of Discovery and Translational Sciences at Metabolon

Dr. Brian Keppler is the Director of Metabolon’s Commercial Discovery and Translational Sciences team and serves as the lead scientific liaison for global business opportunities with pharmaceutical, biotechnology, and applied markets companies. Brian has been with Metabolon since 2011 and manages company efforts toward illuminating novel biological insights and supporting meaningful decision-making to accelerate research and development and advance client success. He received his Ph.D. in Pharmaceutical Sciences from the University of North Carolina at Chapel Hill and completed his postdoctoral training at the National Institute of Environmental Health Sciences in Research Triangle Park, NC.

K
L

Heino Heyman, Ph.D.

Heino HeymanGlobal Field Metabolomics Manager at Metabolon

Dr. Heino M. Heyman is a seasoned Metabolomics professional with an accomplished career spanning over a decade. He embarked on his journey in 2010, utilizing metabolomics to expedite the discovery of active constituents in natural products and to enhance the understanding of resilient crops. In 2015, he joined the Integrative Omics team at Pacific Northwest National Lab, WA, where he broadened the application of metabolomics across diverse sectors, including human, microbial, plant, and soil metabolomics.

Following his postdoctoral studies, he transitioned to the industry, joining Bruker Scientific as a Metabolomics Applications Specialist. He excelled in promoting and demonstrating solutions using sophisticated ion-mobility mass spectrometry instrumentation. In 2020, he joined Metabolon, deepening his involvement in translational science informed by metabolomics. Since 2023, he has been leading a team of metabolomics specialists as Global Metabolomics Application Lead, elevating the metabolomics experience for clients at Metabolon.

WATCH WEBINAR

✕

References

1. Zgoda-Pols, J.R., et al., Metabolomics analysis reveals elevation of 3-indoxyl sulfate in plasma and brain during chemically-induced acute kidney injury in mice: investigation of nicotinic acid receptor agonists. Toxicol Appl Pharmacol, 2011. 255(1): p. 48-56.

2. Bryant, J.A., et al., The impact of an oral purified microbiome therapeutic on the gastrointestinal microbiome. Nat Med, 2026. 32(1): p. 186-196

3. McGovern, B .H., et al., SER-109, an Investigational Microbiome Drugto Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial. Clin Infect Dis, 2021. 72(12): p. 2132-2140.

4. Feuerstadt, P., et al., SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection. N Engl J Med, 2022. 386(3): p. 220-229.

5. Hu, Z., et al., Targeted metabolomics reveals novel diagnostic biomarkers for colorectal cancer. Mol Oncol, 2025. 19(6): p. 1737-1750.

6. Butler, F.M., et al., Vegetarian Dietary Patterns and Diet-Related Metabolites Are Associated With Kidney Function in the Adventist Health Study-2 Cohort. J Ren Nutr, 2025.

7. Stanford, J., et al., Metabolomic Profiling and Diet Quality Scoring in a Randomized Crossover Trial of Healthy and Typical Dietary Patterns. Mol Nutr Food Res, 2025 . 69(23): p. e70271.

8. O’Connor, L.E., et al., Metabolomic Profiling of an Ultraprocessed Dietary Pattern in a Domiciled Randomized Controlled Crossover Feeding Trial. J Nutr, 2023. 153(8): p. 2181-2192.

9. Fritsch, D.A., et al., Microbiome function underpins the efficacy of a fiber-supplemented dietary intervention in dogs with chronic large bowel diarrhea. BMC Vet Res, 2022. 18(1): p. 245.

10. Leal, L.N., et al., Preweaning nutrient supply improves lactation productivity and reduces the risk of culling in Holstein cows. J Dairy Sci, 2025. 108(6): p. 5875-5888.

11. Ahsin, M., et al., Soil and pasture health underlie improved beef nutrient density determined by untargeted metabolomics in Southern US grass finished beef systems. NPJ Sci Food, 2025. 9(1): p. 151.

12. Yin, W., et al., Plasma lipid profiling across species for the identification of optimal animal models of human dyslipidemia. J Lipid Res, 2012. 53(1): p. 51-65.

13. Porter, F .D., et al., Cholesterol oxidation products are sensitive and specific blood-based biomarkers for Niemann-Pick C1 disease. Sci Transl Med, 2010. 2(56): p. 56ra81.

14. Needham, B .D., et al., Plasma and Fecal Metabolite Profiles in Autism Spectrum Disorder. Biol Psychiatry, 2021. 89(5): p. 451-462

15. Li, C., et al., Estradiol and mTORC2 cooperate to enhance prostaglandin biosynthesis and tumorigenesis in TSC2-deficient LAM cells. J Exp Med, 2014. 211(1): p. 15-28.

16. Green, P.G., et al., Metabolic flexibility and reverse remodelling of the failing human heart. Eur Heart J, 2025. 46(25): p. 2422-2433.

17. Maekawa, H., et al., SGLT2 inhibition protects kidney function by SAM-dependent epigenetic repression of inflammatory genes under metabolic stress. J Clin Invest, 2025. 135(19).

18. Wu, D., et al., Integrated screens reveal that guanine nucleotide depletion, which is irreversible via targeting IMPDH2, inhibits pancreatic cancer and potentiates KRAS inhibition. Gut, 2026.

19. Schwerdtfeger, L.A., et al., Gut microbiota and metabolites are linked to disease progression in multiple sclerosis. Cell Rep Med, 2025. 6(4): p. 102055.

20. Wu, H., et al., Microbiome-metabolome dynamics associated with impaired glucose control and responses to lifestyle changes. Nat Med, 2025. 31(7): p. 2222-2231.

21. Jacobs, J.P., et al., Cognitive behavioral therapy for irritable bowel syndrome induces bidirectional alterations in the brain-gut-microbiome axis associated with gastrointestinal symptom improvement. Microbiome, 2021. 9(1): p. 236.

22. Pietzner, M., et al., Plasma metabolites to profile pathways in noncommunicable disease multimorbidity. Nat Med, 2021. 27(3): p. 471-479.

23. Faquih, T.O., et al., Robust Metabolomic Age Prediction Based on a Wide Selection of Metabolites. J Gerontol A Biol Sci Med Sci, 2025. 80(3).

24. Scherer, N., et al., Coupling metabolomics and exome sequencing reveals graded effects of rare damaging heterozygous variants on gene function and human traits. Nat Genet, 2025. 57(1): p. 193-205.

25. Holmes, Z.C., et al., Untargeted metabolomic analysis of human milk from healthy mothers reveals drivers of metabolite variability. Sci Rep, 2024. 14(1): p. 20827.

26. Titz, B., et al., Implications of Ocular Confounding Factors for Aqueous Humor Proteomic and Metabolomic Analyses in Retinal Diseases. Transl Vis Sci Technol, 2024. 13(6): p. 17.

27. Bloom, S.M., et al., Cysteine dependence of Lactobacillus iners is a potential therapeutic target for vaginal microbiota modulation. Nat Microbiol, 2022. 7(3): p. 434-450.

28. Leimer, E.M., et al., Lipid profile of human synovial fluid following intra-articular ankle fracture. J Orthop Res, 2017. 35(3): p. 657-666.